THERIVA BIOLOGICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.42 USD | +0.12% |
|
+2.19% | -2.35% |
Presentation Operator MessageOperator (Operator)Greetings. Welcome to Theriva Biologics 2022 f...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment. SYN-004 (ribaxamase) is designed to degrade certain commonly used intravenous beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage. SYN-020 is a recombinant oral formulation of the enzyme intestinal alkaline phosphatase produced under current good manufacturing practice conditions and intended to treat both local GI and systemic diseases. Its research programs include VCN-11 Albumin Shield Technology and SYN-006, SYN-007, other oncolytic virus.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.42
USD
Average target price
4.5
USD
Spread / Average Target
+971.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.35% | 7.19M | |
| -2.63% | 103B | |
| +1.62% | 95.28B | |
| +1.46% | 22.15B | |
| -16.67% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.21% | 16.05B | |
| +5.41% | 13.68B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- TOVX Stock
- News Theriva Biologics, Inc.
- Transcript : Theriva Biologics, Inc., Q4 2022 Earnings Call, Mar 30, 2023
